Clinical prostate cancer最新文献_第6页

Highlights from the 41st Annual Meeting of the American Society of Clinical Oncology May 2005 and the 2005 American Society of Clinical Oncology Prostate Cancer Symposium February 2005 Orlando, Florida 2005年5月第41届美国临床肿瘤学会年会和2005年2月美国临床肿瘤学会前列腺癌研讨会的亮点

Clinical prostate cancer Pub Date : 2005-06-01 DOI: 10.1016/S1540-0352(11)70098-1

G. Kesava Reddy PhD, Preeta Tyagi PhD, Arif Hussain MD, Vinay K. Jain MD, Oliver Sartor MD

引用次数: 0

Antigen-Presenting Cells 8015 (Provenge®) in Patients with Androgen-Dependent, Biochemically Relapsed Prostate Cancer 抗原呈递细胞8015 (Provenge®)在雄激素依赖性生化复发前列腺癌患者中的应用

Clinical prostate cancer Pub Date : 2005-06-01 DOI: 10.3816/CGC.2005.n.013

Garth Beinart , Brian I. Rini , Vivian Weinberg , Eric J. Small

{"title":"Antigen-Presenting Cells 8015 (Provenge®) in Patients with Androgen-Dependent, Biochemically Relapsed Prostate Cancer","authors":"Garth Beinart , Brian I. Rini , Vivian Weinberg , Eric J. Small","doi":"10.3816/CGC.2005.n.013","DOIUrl":"10.3816/CGC.2005.n.013","url":null,"abstract":"<div><h3>Background</h3><p>Antigen-presenting cells 8015 (APC8015; Provenge®) is an immunotherapeutic product designed to initiate a T-cell–mediated immune response against prostatic acid phosphatase, an antigen overexpressed in 95% of prostate cancer cells. In phase I/II trials, APC8015 has shown immunologic and clinical responses in patients with androgen- independent prostate cancer. This phase II trial was conducted to assess the prostate-specific antigen (PSA)–modulating effects of APC8015 in patients with androgen-dependent prostate cancer (ADPC) with biochemical progression.</p></div><div><h3>Patients and Methods</h3><p>Patients with nonmetastatic recurrent disease as manifested by increasing PSA levels (0.4-6.0 ng/mL) and who had undergone previous definitive surgical or radiation therapy were enrolled. Therapy consisted of APC8015 infusion on weeks 0, 2, and 4 (ie, 3 infusions). Prostate-specific antigen was measured at baseline and monthly until disease progression, defined as a doubling of the baseline or nadir PSA value (whichever was lower) to ≥ 4 ng/mL or development of distant metastases.</p></div><div><h3>Results</h3><p>Thirteen of 18 patients demonstrated an increase in PSA doubling time (PSADT), with a median increase of 62% (4.9 months before treatment vs. 7.9 months after treatment; <em>P</em> = 0.09; signed-rank test).</p></div><div><h3>Conclusion</h3><p>Therapy was well tolerated. APC8015 as single-agent immunotherapy for patients with ADPC and biochemical progression did not result in ≥ 50% decrease in PSA from baseline levels but did appear to modulate PSADT in some patients. Further manipulations of host immunity may be required to achieve a significant antitumor effect.</p></div>","PeriodicalId":87076,"journal":{"name":"Clinical prostate cancer","volume":"4 1","pages":"Pages 55-60"},"PeriodicalIF":0.0,"publicationDate":"2005-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.3816/CGC.2005.n.013","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"25168217","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 61

Prostate-Specific Antigen Endpoints in Hormone-Refractory Prostate Cancer 激素难治性前列腺癌的前列腺特异性抗原终点

Clinical prostate cancer Pub Date : 2005-06-01 DOI: 10.3816/CGC.2005.n.006

Oliver Sartor MD , Daniel George MD

引用次数: 1

The “Emigration, Migration, and Immigration” of Prostate Cancer 前列腺癌的“迁出、迁出、迁入”

Clinical prostate cancer Pub Date : 2005-06-01 DOI: 10.3816/CGC.2005.n.008

Kenneth J. Pienta, Robert Loberg

引用次数: 50

Highlights from the 2005 American Society of Clinical Oncology prostate Cancer Symposium Orlando, Florida February 17-19, 2005 2005年美国临床肿瘤学会前列腺癌症专题讨论会纪要2005年2月17日至19日，佛罗里达州奥兰多

Clinical prostate cancer Pub Date : 2005-03-01 DOI: 10.1016/S1540-0352(11)70087-7

G. Kesava Reddy PhD, Tara Beers Gibson PhD, Thomas Hutson DO, PharmD, Sara Marianni MD, Oliver Sartor MD

引用次数: 0

Update on Fused Capromab Pendetide Imaging of Prostate Cancer 前列腺癌融合卡普罗马单肽显像研究进展

Clinical prostate cancer Pub Date : 2005-03-01 DOI: 10.3816/CGC.2005.n.004

D. Bruce Sodee , A. Dennis Nelson , Peter F. Faulhaber , Gregory T. MacLennan , Martin I. Resnick , George Bakale

{"title":"Update on Fused Capromab Pendetide Imaging of Prostate Cancer","authors":"D. Bruce Sodee , A. Dennis Nelson , Peter F. Faulhaber , Gregory T. MacLennan , Martin I. Resnick , George Bakale","doi":"10.3816/CGC.2005.n.004","DOIUrl":"10.3816/CGC.2005.n.004","url":null,"abstract":"<div><p>The primary objective of this overview is to apprise clinical urologists and oncologists of the current state of fused multimodality imaging of prostate cancer, which can be applied to optimize treatment by ensuring that a patient's disease is characterized as well as current imaging technology permits. The focus of this study is the monoclonal antibody capromab pendetide, which targets prostate specific membrane antigen (PSMA), a type II membrane glycoprotein strongly associated with prostate cancer. Identifying where capromab pendetide uptake occurs can be done accurately if this functional imaging modality is combined with a modality that provides anatomic detail, such as computed tomography (CT) or magnetic resonance imaging (MRI). Image fusion, or coregistration, which is overlaying the functional images of capromab pendetide uptake on the anatomic CT or MRI images, provides a detailed map of cancer localization inside and outside the prostate gland. This same principle of fusing functional images on anatomic images is the basis for enormous growth of positron emission tomography with CT during the past 2 years. Positron emission tomography imaging has a different functionality base than does capromab pendetide, and thus the 2 modalities should be complementary. However, the key to both functional imaging modalities is accurate fusion with anatomic images, which is illustrated in our case reports. The cases cited demonstrate the need to optimize every phase of imaging from patient preparation to reading and reporting increased PSMA concentration seen on the fused images. Reference is also made to applying capromab pendetide/CT fused imaging to radiation therapy planning.</p></div>","PeriodicalId":87076,"journal":{"name":"Clinical prostate cancer","volume":"3 4","pages":"Pages 230-238"},"PeriodicalIF":0.0,"publicationDate":"2005-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.3816/CGC.2005.n.004","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"25272948","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 42

Role of 5αReductase Inhibitors and Selective Estrogen Receptor Modulators as Potential Chemopreventive Agents for Prostate Cancer 5α还原酶抑制剂和选择性雌激素受体调节剂作为潜在的前列腺癌化学预防剂的作用

Clinical prostate cancer Pub Date : 2005-03-01 DOI: 10.1016/S1540-0352(11)70089-0

Nancy Price PhD, Oliver Sartor MD, Thomas Hutson DO, PharmD, Sara Marianni MD

引用次数: 4

Is There a Role for Less Invasive Therapeutic Approaches for Low- and Intermediate-Grade Organ-Confined Prostate Cancer? 低、中级别器官局限性前列腺癌有微创治疗的作用吗?

Clinical prostate cancer Pub Date : 2005-03-01 DOI: 10.3816/CGC.2005.n.001

Oliver Sartor MD (Editor-in-Chief)

引用次数: 0

Genetic Alterations in Prostate Cancer 前列腺癌的基因改变

Clinical prostate cancer Pub Date : 2005-03-01 DOI: 10.3816/CGC.2005.n.003

Evan Y. Yu , William C. Hahn

引用次数: 1

Lifestyle Correlates of Health Perception and Treatment Satisfaction in a Clinical Cohort of Men with Prostate Cancer 前列腺癌男性临床队列中生活方式与健康感知和治疗满意度相关

Clinical prostate cancer Pub Date : 2005-03-01 DOI: 10.3816/CGC.2005.n.005

Sara K. Sheriff , Ryo A. Shohara , Sarah B. Dumican , Eric J. Small , Peter R. Carroll , June M. Chan

{"title":"Lifestyle Correlates of Health Perception and Treatment Satisfaction in a Clinical Cohort of Men with Prostate Cancer","authors":"Sara K. Sheriff , Ryo A. Shohara , Sarah B. Dumican , Eric J. Small , Peter R. Carroll , June M. Chan","doi":"10.3816/CGC.2005.n.005","DOIUrl":"10.3816/CGC.2005.n.005","url":null,"abstract":"<div><p>There is a growing need to understand how nutritional and lifestyle practices may optimize quality of life (QOL) and health after diagnosis for the 1.5 million men living with prostate cancer in the United States. We are establishing a clinical cohort of men with prostate cancer at the University of California San Francisco. Men completed detailed dietary and lifestyle questionnaires annually and provided consent for blood and tissue specimens to be stored for research if they underwent radical prostatectomy. We examined the feasibility of establishing this cohort and analyzed preliminary baseline data on participant demographics, lifestyle habits, and QOL using χ<sup>2</sup> and t-tests and logistic regression models. Between February 2002 and July 2004, we enrolled 343 men with prostate cancer into the survey portion of this cohort. The response rate was approximately 85% via in-clinic enrollment and 30% via mail enrollment. Based on analysis of the first 193 men enrolled, there was a high level of treatment satisfaction in this population (88% of men were satisfied or extremely satisfied with treatment) and positive reports of general health perception (73% of men perceived themselves to be in excellent [34%] or very good [39%] health). Whether treatment interfered with diet was an independent predictor of health perception and treatment satisfaction. Use of dietary supplements was high (90%) in this well-educated population. In conclusion, we demonstrated good feasibility for conducting this longitudinal study and observed initial indications that diet and other lifestyle practices were important predictors of patient QOL.</p></div>","PeriodicalId":87076,"journal":{"name":"Clinical prostate cancer","volume":"3 4","pages":"Pages 239-245"},"PeriodicalIF":0.0,"publicationDate":"2005-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.3816/CGC.2005.n.005","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"25100831","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 3